

**REVIEW ARTICLE**

## Pharmacological Effects of Dexamphenol

**Solaiman Doba<sup>1</sup>, Anna Buzlama<sup>2</sup>, Alexander Kuznetsov<sup>2</sup>**

<sup>1</sup>Department of Pharmacology and Toxicology, Faculty of Pharmacy, Manarauniversity, Syria.

<sup>2</sup>Department of Pharmacology and Clinical Pharmacology,  
Faculty of Pharmacy, Voronezh State University, Russia.

\*Corresponding Author E-mail: [suliman.doba@manara.edu.sy](mailto:suliman.doba@manara.edu.sy), [silversleman23@gmail.com](mailto:silversleman23@gmail.com),  
[buzlama@pharm.vsu.ru](mailto:buzlama@pharm.vsu.ru), [buzlamaa@yandex.ru](mailto:buzlamaa@yandex.ru)

### **ABSTRACT:**

This article focuses on examining and combining published information regarding the latest pleiotropic pharmacological impacts of dexamphenol. Particular attention in this article is paid to the pharmacological protective effects of dexamphenol on the kidneys, liver, brain and nerves, gastrointestinal tract, and the cardiovascular and respiratory systems. In general, a substantial amount of experimental and clinical data has been accumulated, which allows us to conclude that further investigation into the pleiotropic effects of dexamphenol holds promise. A wide range of target organs and tissues, coupled with its low toxicity, make dexamphenol a promising ingredient for the development of new drugs. The most promising effects for further study are antioxidant, anti-inflammatory, gastroprotective, hepatoprotective, and neuroprotective effects. It is particularly crucial to investigate the efficacy of dexamphenol through alternative methods of administration, in addition to the established external use and intraperitoneal route of administration used in preclinical studies. For instance, oral administration should be explored, encompassing a broad range of doses, including smaller ones. The development of various local dosage forms, such as gels, wound dressings, ophthalmic films, and others, as well as liquid forms like solutions and syrups, and solid forms like capsules with liquid contents, is significant. These developments have the potential to expand the clinical applications of dexamphenol in various fields, including dermatology, gastroenterology, neurology, and general internal medicine.

**KEYWORDS:** Dexamphenol, Pleiotropic effects, Pharmacological effects, Nephroprotective, Hepatoprotective, Neuroprotective, Gastroprotective, Cardioprotective, Pulmoprotective drugs.

### **INTRODUCTION:**

Dexamphenol is an amide of a monocarboxylic acid with hydroxy groups at specific positions and a 3-hydroxypropyl group attached to the carbonyl nitrogen<sup>1,2</sup>. Dexamphenol functions as a provitamin B<sub>5</sub> and shares a resemblance to pantothenic acid. Pantothenic acid is a vital component of coenzyme A, which plays a crucial role in cellular metabolism as the coenzyme acetyl CoA. Pantothenic acid is crucial for the development and rejuvenation of the skin and mucous membranes<sup>3</sup>.

Dexamphenol is considered non-toxic with an oral LD<sub>50</sub> of 15g/kg in mice, but side effects and allergic reactions have been reported<sup>4,5,6</sup>. Although contact allergy to dexamphenol is rare<sup>7,8</sup>. The authenticity of dexamphenol is determined by IR spectroscopy, and quantitative determination is done chemically using perchloric acid. In this review we mentioned the newest well-studied pleiotropic effects of dexamphenol on different body organs.

#### **1. Wound healing effect of dexamphenol:**

The application of dexamphenol on the skin to treat skin conditions is well-documented. Research has shown that using dexamphenol topically can help accelerate the healing of minor wounds. Dexamphenol initiates the activation of essential genes involved in the healing process, thereby expediting wound healing through the

facilitation of re-epithelialization and the restoration of the skin's barrier function<sup>9</sup>. The application of topical dexpanthenol serves as a moisturizing agent that improves skin hydration, diminishes water loss, and maintains the skin's suppleness and elasticity<sup>10</sup>. Dexpanthenol has been shown to promote the proliferation of fibroblasts, a crucial factor in the process of wound healing. Both *in vitro* and *in vivo*, the application of dexpanthenol has been associated with enhanced re-growth of epithelial cells, thereby expediting the overall wound healing process<sup>11</sup>. Moreover, there have been documented instances of expedited re-epithelialization in the context of wound healing, where the preservation of the epidermal barrier integrity is evaluated through the measurement of transepidermal water loss as an indicator<sup>12</sup>. Furthermore, the application of a heparin-allantoin-dexpanthenol ointment has demonstrated the anti-inflammatory properties of dexpanthenol on UV-induced erythema in guinea pigs<sup>13</sup>. Dexpanthenol undergoes metabolic conversion within the body to yield pantothenic acid, where it functions as a constituent of coenzyme A. Coenzyme A is essential for facilitating the early steps of fatty acid and sphingolipid production, which are vital for preserving the structure of lipid bilayers in the stratum corneum and cellular membranes. The use of dexpanthenol has shown significant improvements in skin barrier repair, hydration of the stratum corneum, as well as a reduction in skin roughness and inflammation<sup>14</sup>. Due to extensive research on the wound-healing properties of dexpanthenol, it is evident that ointments and creams are the primary topical treatments used in dermatology. However, there is great potential in diversifying the range of local dosage forms for skin and mucous membrane application. This includes the development of hydrogels, patches, and wound coverings, which hold promise in enhancing the effectiveness of dexpanthenol.

## 2. The nephroprotective effect of dexpanthenol:

The impact of dexpanthenol in protecting rats against gentamicin-induced nephrotoxicity was examined<sup>15</sup>. This research demonstrates that the administration of dexpanthenol can mitigate the nephrotoxic effects induced by gentamicin. The rats in the study were intraperitoneally injected with dexpanthenol at a dosage of 500mg/kg for a duration of 8 days. In the group treated with dexpanthenol, there were notable reductions in the levels of urea, creatinine, tumor necrosis factor-alpha, total oxidant status, oxidative stress index, and malondialdehyde in comparison to the group treated solely with gentamicin. Furthermore, the levels of catalase and glutathione peroxidase were notably increased in the gentamicin/dexpanthenol group. Histological analysis revealed pronounced tubular necrosis in the gentamicin group, whereas this condition

was less severe in the dexpanthenol group<sup>16</sup>. In a separate investigation, researchers examined the potential protective impact of dexpanthenol against cisplatin-induced nephrotoxicity in rats<sup>17</sup>. The experimental group received a one-time administration of cisplatin, followed by a daily dosage of 500 mg/kg of dexpanthenol over a span of 10 days. Results indicated a reduction in levels of malondialdehyde, blood urea nitrogen, and creatinine, alongside an elevation in superoxide dismutase, catalase, glutathione peroxidase, and myeloperoxidase levels within the dexpanthenol-treated group. The group administered with dexpanthenol demonstrated reduced damage and inflammation in the renal tubules in contrast to the group treated with Cisplatin. The antioxidant and anti-inflammatory characteristics of dexpanthenol suggest its potential therapeutic efficacy in managing cisplatin-induced nephrotoxicity<sup>18</sup>. In another study, researchers examined the protective and healing properties of dexpanthenol in mitigating kidney injury caused by ischemia-reperfusion in rats. Dexpanthenol was delivered via intraperitoneal administration at a dosage of 500mg/kg prior to ischemia, during ischemia, and throughout the late reperfusion phase. The findings indicated that dexpanthenol effectively alleviated renal ischemia-reperfusion damage by diminishing significant tubular necrosis, glomerular impairment, and apoptosis as observed in histological assessments<sup>19</sup>. Experimental studies have shown that dexpanthenol possesses antioxidant properties and has the capacity to enhance renal function. The research utilized a dosage of 500 mg/kg delivered intraperitoneally, resulting in observed nephroprotective benefits. This data showed that dexpanthenol can play a promising role in the development of new nephroprotective drugs. In contrast, a dose of 500mg/kg appears to be a significant amount. Additionally, intraperitoneal administration is not a comfortable route for humans. Therefore, it is recommended to prepare dexpanthenol in a solution for injection and administer it through an alternative route, such as intravenous drip. This would make it technically feasible to administer the high dose.

## 3. The hepatoprotective effect of dexpanthenol:

The hepatoprotective effects of dexpanthenol in mitigating liver injuries induced by ischemia-reperfusion was examined *In vivo*. Results from this study demonstrated that pre-treatment with dexpanthenol successfully reduced oxidative stress and increased antioxidant levels in the rat model subjected to liver ischemia-reperfusion. The intraperitoneal administration of dexpanthenol at a dosage of 500mg/kg, administered 30 minutes prior to a 60-minute ischemic event followed by 60 minutes of reperfusion, resulted in notable enhancements in overall glutathione levels and effectively mitigated the heightened myeloperoxidase

production in rat subjects. Furthermore, the administration of dexamphenol led to a reduction in histological tissue damage in both the dexamphenol and dexamphenol combined with ischemia-reperfusion groups<sup>20</sup>. In a research study by Mukaddes Gurler et al., the protective potential of dexamphenol against liver oxidative damage induced by methotrexate in rats was investigated. Dexamphenol was delivered intraperitoneally at a dosage of 500mg/kg/day over a period of 24days. The findings indicated that dexamphenol exhibited a mitigating effect on the hepatotoxicity induced by reactive oxygen species resulting from methotrexate exposure. The enhancement was noted in relation to the antioxidant/oxidant enzymes of liver tissue, liver function assessments, and histological alterations. Consequently, it was recommended that dexamphenol could be utilized in conjunction with methotrexate therapy to mitigate liver toxicity<sup>21</sup>. Another researcher examined the protective effects of dexamphenol at a dose of 500mg/kg intraperitoneally against acetaminophen-induced oxidative hepatorenal damage<sup>22,23</sup>. The study indicated that dexamphenol led to a notable reduction in oxidant levels in the liver and kidney tissues, along with an elevation in antioxidant levels compared to the acetaminophen group. Additionally, findings from biochemical and histological evaluations demonstrated that dexamphenol exhibited hepatoprotective effects similar to those of N-acetylcysteine<sup>24</sup>. Another research experiment was conducted to examine the impact of dexamphenol on diabetic rats induced with streptozotocin. Streptozotocin is a commonly utilized agent for inducing diabetes in animal models<sup>25</sup>. Diabetes was experimentally induced through a single intraperitoneal dose of streptozotocin at a concentration of 50mg/kg. Following streptozotocin administration, one group was initiated on a daily intraperitoneal regimen of 300mg/kg of dexamphenol for a duration of 6 weeks. The group subjected to dexamphenol treatment demonstrated a partial restoration of normal hepatic parenchyma. The results of histochemical analyses demonstrated that the reduction in glycogen levels caused by diabetes was notably ameliorated through the administration of dexamphenol. The supplementation of dexamphenol in this group led to a decrease in the severity of degenerative changes. Levels of IL-1 $\alpha$  and MCP-1 were comparable to those in the control group. These findings indicate that dexamphenol exhibits efficacy in mitigating diabetic complications induced by streptozotocin and could offer therapeutic advantages for individuals with diabetes<sup>26</sup>. We can suggest that the administration of dexamphenol may help prevent hepatotoxicity, inflammation, and necrosis. The development of new hepatoprotective drugs containing dexamphenol in oral or injectable dosage forms should be considered relevant. The most promising application

of dexamphenol is specifically for drug-induced liver damage.

#### 4. The neuroprotective and behavioral effects of dexamphenol:

The neuroprotective effects of dexamphenol were studied in rats with traumatic brain injury. Dexamphenol was administered intraperitoneally at a dosage of 500 mg/kg. The group treated with dexamphenol exhibited reduced neuronal damage in the cortices under microscopic observation following traumatic brain injury. Consequently, findings suggest that dexamphenol mitigates oxidative damage, inhibits apoptosis through the activation of antioxidant mechanisms, and mitigates brain injury resulting from traumatic brain injury<sup>27</sup>. The behavioral effect of dexamphenol in animals have not been adequately established. Salimİnan and YağmurAçıkgoz conducted a study to investigate the anticonvulsant properties of dexamphenol on seizures induced by Pentylenetetrazole, a GABA receptor antagonist commonly employed to induce chemically-induced seizures in research settings<sup>28</sup>. Of all the animal models used to study seizures and epilepsy, pentylenetetrazole-induced seizures are classified as a model representing generalized seizures, as opposed to partial or focal seizures. Additionally, the antidepressant-like effect was evaluated using the forced swim test. The forced swim test is a rodent behavioral test used for evaluation of antidepressant drugs, antidepressant efficacy of new compounds<sup>29</sup>. In their study, it was documented that the administration of dexamphenol at a dosage of 500mg/kg via intraperitoneal injection resulted in notable antiepileptic and antidepressant properties, while not impacting motor function<sup>30</sup>. The findings of this study suggest that dexamphenol demonstrates potential as a beneficial clinical intervention for managing pain and nerve injury. To induce a crush injury, the right sciatic nerve of all rats was clamped for a duration of one minute. In a specific experimental group, a dosage of 500mg/kg of dexamphenol was administered intraperitoneally one day prior to the surgical procedure. This dosage was continued three times a week for a period of 28 days during the experiment. In another experimental group, rats received a dose of 10mg/kg of dexamphenol to investigate the potential effects of dexamphenol alone. The performance of the groups administered with dexamphenol showed a notable increase during the rotarod test at both 30rpm and 40rpm. Subsequently, there was a significant rise in the number of rats capable of sustaining their position on the rod in these two groups during the acceleration test. Hot plate latency test results were also significantly higher in the dexamphenol groups<sup>31</sup>. In this study, the comparative effectiveness of a low dose of 10mg/kg and a high dose of 500 mg/kg is of particular interest, which makes

further studies on the effects of dexamphenol in small dose ranges promising. Due to the analysis of the data indicating potential neuroprotective, anticonvulsant, and antidepressant effects, as well as unclear and contradictory findings regarding its impact on muscle tone control, further research in this area is recommended. In any case, the specified list of pharmacological effects indicates the potential of using dexamphenol as a nootropic and neurometabolic agent.

### 5. The gastrointestinal effect of dexamphenol:

The efficacy of dexamphenol in treating ulcers has been documented not in its isolated form but as part of a mixture. This study utilized an oral administration of dexamphenol at a dosage of 6.88mg/kg. This research has indicated that a chitosan-based gel incorporating dexamphenol exhibits notable gastroprotective properties in experimental models of NSAID-induced gastropathy, both in preventive and therapeutic regimens, as well as in stress-induced ulcer formation. It decreases the quantity and size of ulcerative lesions and mitigates the effects of organ-specific toxicity induced by NSAIDs. In this study, it was revealed that the gel diminishes the symptoms of organ-specific toxicity caused by diclofenac sodium. Additionally, it exhibits gastroprotective effects, anti-inflammatory, hepatoprotective, and hemostatic properties<sup>32,33</sup>. These results are consistent with literature data. The therapeutic potential of dexamphenol was elucidated on the amelioration of colitis in rats. Colitis was provoked through the rectal administration of a single dose of 4% acetic acid into the colon for three consecutive days. 4% acetic acid solution led to the development of intense and profound colitis, accompanied by a notably elevated mortality rate<sup>34</sup>. In the experimental group, beginning on the fourth day, a single dose of dexamphenol at a dosage of 500mg/kg was given intraperitoneally for three consecutive days. Total oxidant status and oxidative stress index levels in the dexamphenol group were reduced compared to the acetic acid group. However, no significant increase in total antioxidant capacity levels was detected. The use of dexamphenol resulted in positive changes in both biochemical and histopathological aspects, suggesting that dexamphenol could potentially act as an antioxidant in treating colitis<sup>35</sup>. The anti-ulcer and anti-colitis activity of

dexamphenol was not clearly reported. The anti-ulcer effect of dexamphenol itself was not studied, but rather a mixture containing dexamphenol prepared in a chitosan-based gel. The anti-colitis effect was studied on a single model using a single dose and only one route of administration. However, further research in the area of gastroprotective activity is promising, considering the well-studied regenerative activity of dexamphenol. This includes the potential development of oral dosage forms of dexamphenol, such as liquid (solution, syrup) or solid (capsules with liquid contents), for the treatment of hyperacid gastritis, ulcerative diseases of the stomach and duodenum, as well as the treatment and prevention of NSAID gastropathy and stress ulcers.

### 6. The respiratory and cardiovascular protective effect of dexamphenol:

A study documented a protective effect of pantothenic acid against bleomycin-induced pulmonary fibrosis in rats. For the experimental group, 500mg/kg of dexamphenol was administered intraperitoneally 1 hour before the intratracheal bleomycin injection and continued for 14 days. It was shown that dexamphenol significantly prevents bleomycin-induced lung fibrosis in rats<sup>36</sup>. Another research study examined the anti-inflammatory and anti-oxidative properties of dexamphenol in vivo of acute lung injury induced by lipopolysaccharide. Lipopolysaccharide is known to trigger acute lung injury and alveolar hemorrhage through the cytokine storm<sup>37</sup>. Intraperitoneal administration of Dexamphenol at a dosage of 500 mg/kg resulted in a notable decrease in pulmonary edema. Findings indicate that Dexamphenol demonstrates a protective influence in this particular model by virtue of its anti-inflammatory and antioxidant properties<sup>38</sup>. Therefore, it can be inferred that the protective impact of dexamphenol on the respiratory and cardiovascular systems primarily stems from its anti-inflammatory and antioxidant properties. However, further studies should be conducted to explore additional dosing options and routes of administration in order to gather more data for the development of new drugs containing dexamphenol. It is also promising to study the direct anti-inflammatory effect of dexamphenol on specific models of inflammation.

**Tabl 1: Pleiotropic effects of dexamphenol:**

Organ	Effect	Dose	In vivo model
Skin	Wound healing, anti-inflammatory effect <sup>9-14</sup> , topical administration	5%	Lesions (superficial wounds) of the skin and mucous membranes
Kidneys	Nephroprotective effect <sup>16-19</sup> , intraperitoneal administration	500 mg/kg, 8 days	Gentamicin-induced nephrotoxicity
		500 mg/kg, 10 days	Cisplatin-induced nephrotoxicity
		500 mg/kg, before, during ischemia and late reperfusion	Ischemia-reperfusion
Liver	Hepatoprotective, antioxidant, anti-inflammatory effect <sup>20-26</sup> , intraperitoneal administration	500 mg/kg for 30 min before 60 min of ischemia, followed by 60 min of reperfusion	Ischemia-reperfusion-induced liver injury

		500 mg/kg/day, 24 days	Methotrexate-induced liver oxidative toxicity
		500 mg/kg	Acetaminophen-induced oxidative hepatorenal damage
		300 mg/kg/day, 6 weeks	Streptozotocine-induced diabetic
Brain/ Nerves	Neuroprotective effect <sup>27-31</sup> , Intraperitoneal administration	500 mg/kg	Induced traumatic brain injury
		500 mg/kg	Sciatic nerve injury
Gastrointestinal tract	Antiepileptic, antidepressant-like effects <sup>30</sup> , intraperitoneal administration	500 mg/kg	Antiepileptic: convulsions caused by pentylenetetrazole; antidepressants: forced swim test
	Gastroprotective, hepatoprotective, anti-inflammatory, hemostatic properties <sup>32,33</sup> , oral administration	6.88 mg/kg	NSAIDs, stress, and ethanol induced stomach ulcer
Respiratory and Cardiovascular system	Anti-colitis effect <sup>35</sup> , intraperitoneal administration	500 mg/kg/day, 3 days	Acetic acid-induced colitis
	Respiratory protective effect <sup>36,38</sup> , intraperitoneal administration	500 mg/kg, 1 hour before of bleomycin, 14 days	Bleomycin-induced pulmonary fibrosis
		500 mg/kg	Lipopolysaccharide-induced acute lung injury

## CONCLUSION:

The pleiotropic effects of dexamethasone include its protective effects on the kidneys, liver, brain and nerves, gastrointestinal tract, and the cardiovascular and respiratory systems (table. 1). The precise mechanism underlying the pleiotropic effects of dexamethasone has not been fully elucidated. However, it is established that the application of antioxidants can mitigate the detrimental impacts of free radicals in the context of inflammation<sup>39</sup>. Dexamethasone acts as an antioxidant by elevating the concentrations of reduced glutathione, coenzyme A, and promoting ATP synthesis. These mechanisms play a vital role in protecting cells against oxidative stress, thereby influencing the reduction of inflammatory reactions and accelerating the healing process. These results are believed to be a result of the synergistic impact of its antioxidant and anti-apoptotic characteristics. Research has firmly established that dexamethasone demonstrates significant capabilities in scavenging free radicals and providing antioxidant benefits in both in vivo and in vitro investigations<sup>37, 38</sup>. In most of the studies reviewed, it can be concluded that dexamethasone has beneficial effects on the tissue level due to its anti-inflammatory properties and protective effects against oxygen free radicals, as indicated by biochemical and histopathological results.

A substantial body of experimental and clinical evidence has been gathered, supporting the potential for additional research on the multifaceted impacts of dexamethasone. Given its broad spectrum of target organs and tissues, as well as its minimal toxicity profile, dexamethasone emerges as a favorable candidate for the formulation of novel pharmaceuticals. Particularly noteworthy are its antioxidant, anti-inflammatory, gastroprotective, hepatoprotective, and neuroprotective properties, which warrant further investigation. It is imperative to explore the effectiveness of dexamethasone using alternative modes of delivery, in conjunction with

the conventional methods of topical application and intraperitoneal administration employed in preclinical research. For example, it is important to investigate the oral delivery method across a wide spectrum of dosages, including lower amounts. The creation of diverse localized dosage formats such as gels, wound coverings, ophthalmic films, and similar products, as well as liquid formulations such as solutions and syrups, and solid formulations like capsules containing liquid components, holds considerable importance<sup>40-43</sup>. These developments have the potential to broaden the clinical applications of dexamethasone in fields such as dermatology, gastroenterology, neurology, and general internal medicine.

## REFERENCES:

1. EMBL's European Bioinformatics Institute: CHEBI:27373 – pantothenol [online]. Available from: <https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:27373> (Last accessed 03.05.2023).
2. Dexamethasone: British Pharmacopoeia 2009. Medicines and Healthcare products Regulatory Agency (MHRA). 6th Edition. London, 2008: Vol. I&II. 1828-1830.
3. National Cancer Institute Dexamethasone (Code C47481) [online]. Available from: <https://ncit.nci.nih.gov> (Last accessed 03.05.2023).
4. Jakob HM, et al. Information und Beratung "Dexamethasone". Deutsche Apotheker-Zeitung. 1995; 135: 2102-2104.
5. Hahn C, et al. Allergic contact reaction to dexamethasone: lymphocyte transformation test and evidence for microsomal-dependent metabolism of the allergen. Contact Dermatitis. 1993; 28: 81-83. Doi: 10.1111/j.1600-0536.1993.tb03346.x.
6. Botz C, et al. Allergic sensitization to dexamethasone and exacerbation of eczema by orally ingested pantothenic acid. Journal of Allergy and Clinical Immunology. 1997; 99: 336.
7. Riedl B, et al. Type IV-allergies to components of ophthalmica. Klinische Monatsblatterfur Augenheilkund. 1991; 198: 251-254.
8. Schmid-Grendelmeier P, Wyss M, Elsner P. Kontaktallergiegegen Dexamethasone: Ein Bericht über sieben Fälle und ein Literaturüberblick. Dermatologie in Beruf und Umwelt. 1995; 43: 175-178.
9. Gorski J, et al. Dexamethasone in Wound Healing after Medical and Cosmetic Interventions (Postprocedure Wound Healing). Pharmaceuticals. 2020; 13(7): 138. DOI: 10.3390/ph13070138.
10. Vimodrone MI. Vitamine in dermatologia e cosmesi. Cosmet News. 1992; 15: 99-104.

11. Abdel Hamid M, et al. Evaluation of the biological activity of some medicated solidified sodium stearate-based sticks (SSSS). *Drug Dev Ind Pharm.* 1984; 10: 685-97.
12. Levy JJ, et al. Validation of an in vivo wound healing model for the quantification of pharmacological effects on epidermal regeneration. *Dermatology.* 1995; 190: 136-141.
13. Tauschel HD, Rudolph C. Studies on the percutaneous effectiveness of a heparin-allantoin-dexpanthenol combination in a special ointment base: anti-inflammatory effect on UV erythema in guinea pigs [in German]. *Arzneimittel Forschung.* 1982; 32(2): 1096-1100.
14. Proksch E, Nissen HP. Dexpanthenol enhances skin barrier repair and reduces inflammation after sodium lauryl sulphate-induced irritation. *Journal of Dermatological Treatment.* 2002; 13(4): 173-178. Doi: 10.1080/09546630212345674.
15. Kashyap S, et al. Nephroprotective Effect of Luteolin against Gentamicin-induced Nephrotoxicity in Albino Rats. *Res. J. Pharma. Dosage Forms and Tech.* 2019; 11(4): 253-256.
16. Pinar N, et al. Protective effect of dexpanthenol on gentamicin-induced nephrotoxicity in rats. *Annals of Medical Research.* 2019; 26(9): 1787-91. DOI: 10.5455/annalsmedres.2019.07.435.
17. Gitanjalee CS and Pushparaj RP. Protective effect of Rosinidin on Cisplatin-Induced Nephrotoxicity. *Asian Journal of Research in Pharmaceutical Sciences.* 2023; 13(1): 69-2.
18. Pinar N, et al. Protective effect of dexpanthenol on cisplatin induced nephrotoxicity in rats. *Biotechnic and Histochemistry.* 2021; 97(1): 39-43. Doi: 10.1080/10520295.2021.1890215.
19. Altintas R, Parlakpinar H, Beytur A. Protective Effect of Dexpanthenol on Ischemia-Reperfusion-Induced Renal Injury in Rats. *Kidney Blood Press Res.* 2013; 36(1): 220-230. Doi: 10.1159/000343411.
20. Ucar M, et al. Protective Effect of Dexpanthenol on Ischemia-Reperfusion-Induced Liver Injury. *Transplantation Proceedings.* 2018; 50(10): 3135-3143. Doi: 10.1016/j.transproceed.2018.07.012.
21. Gürler M, et al. Protective effect of dexpanthenol against methotrexate-induced liver oxidative toxicity in rats. *Drug and Chemical Toxicology.* 2022; 46(4): 708-716. Doi: 10.1080/01480545.2022.2084103.
22. Sreedhar V, et al. Hepatoprotective Activity of Vitexquinata Roots against Paracetamol-Induced Hepatic Injury in Rats. *Research J. Pharmacognosy and Phytochemistry.* 2011; 3(2): 77-81.
23. Selvanayaki R, Ananthi T. Hepatoprotective Activity of Aqueous Extract of Lawsonia inermis against Paracetamol Induced Rats. *Asian J. Pharm. Res.* 2012; 2(2): 75-77.
24. Uysal HB, et al. Protective effects of dexpanthenol against acetaminophen-induced hepatorenal damage. *Biomedical Research.* 2017; 28(2): 740-749.
25. Chitra Devi MR, Ramesh B. Hypoglycemic activity of Leaves of Bougainvillea spectabilis extract in Streptozotocin-Induced Diabetic Rats. *Asian J. Pharm. Res.* 2018; 8(2): 99-103.
26. Gulle K, et al. The effects of dexpanthenol in streptozotocin-induced diabetic rats: histological, histochemical and immunological evidences. *Histol Histopathol.* 2014; 29(10): 1305-1313. Doi: 10.14670/HH-29.1305.
27. Bektasoglu PK, et al. Antioxidant and neuroprotective effects of dexpanthenol in rats induced with traumatic brain injury. *Injury.* 2023; 54(4): 1065-1070. Doi: 10.1016/j.injury.2023.02.025.
28. Sooraj S, et al. Facilitatory effect of Piperine on the Anticonvulsant effect of Sodium valproate against Pentylenetetrazole induced Seizures in mice. *Research J. Pharm. and Tech.* 2020; 13(2): 651-652.
29. Praveen Kumar U, et al. Evaluation of anti-depressant activity of Methanolic Seed Extract of Avena sativa L. In Mice. *Research J. Pharmacology and Pharmacodynamics.* 2013; 5(4). 212-217.
30. İnan S, Açıkgöz Y. The Antiepileptic and Antidepressant-Like Effects of Dexpanthenol in Female Swiss Albino Mice. *Clinical and Experimental Health Sciences.* 2022; 12(1): 141-144. DOI: 10.33808/clinexphealthsci.865421.
31. Korkmaz MF, et al. The therapeutic efficacy of dexpanthenol on sciatic nerve injury in a rat model. *British Journal of Neurosurgery.* 2020; 34(4): 397-401. Doi: 10.1080/02688697.2020.1749984.
32. Buzlama AV, Doba S. Evaluation of gastroprotective activity of a chitosan-based gel containing dexamethasone. *Research Results in Pharmacology.* 2022; 8(4): 43-55. Doi: 10.3897/rrpharmacology.8.84777.
33. Solaiman D, Anna B. Protective effect of three developed gel formulations: Chitosan, Chitosan with Taurine and Chitosan with Dexamethasone, on the acute overdose of Diclofenac sodium in preclinical studies. *Research Journal of Pharmacy and Technology.* 2021; 14(8): 4341-4348.
34. Samyuktha G and Charan NS. Effect of Methanolic seed extract of Piper nigrum against Acetic acid induced Ulcerative colitis in rats. *Res. J. Pharmacology and Pharmacodynamics.* 2019; 11(2): 62-66.
35. Cagin YF, et al. Effects of dexpanthenol on acetic acid-induced colitis in rats. *Exp Ther Med.* 2016; 12(5): 2958-2964. Doi: 10.3892/etm.2016.3728.
36. Ermis H, et al. Protective effect of dexpanthenol on bleomycin-induced pulmonary fibrosis in rats. *Naunyn-Schmiedeberg's Arch Pharmacol.* 2013; 386: 1103-1110. Doi: 10.1007/s00210-013-0908-6.
37. Gomathi S, et al. Pedalium murex Linn leaves against LPS-induced oxidative stress, anxiety and depression behavioural alterations in rats. *Research J. Pharm. and Tech.* 2017; 10(5): 1333-1338.
38. Li-Mei W, et al. Anti-inflammatory and Anti-oxidative Effects of Dexpanthenol on Lipopolysaccharide Induced Acute Lung Injury in Mice. *Inflammation.* 2016; 39: 1757-1763. Doi: 10.1007/s10753-016-0410-7.
39. Hassan A, Martin E, Puig-Parellada P. Role of antioxidants in gastric mucosal damage induced by indomethacin in rats. *Methods and Findings in Experimental and Clinical Pharmacology.* 1998; 20(10): 849-854.
40. Bielfeldt S, et al. Efficacy of a new hand care system (cleansing oil and cream) in a model of irritation and in atopic hand eczema. *Dermatosen in Beruf und Umwelt.* 1998; 46: 159-165.
41. Fooanant S, Chaiyasate S, Roongrotwattanasiri K. Comparison on the Efficacy of Dexpanthenol in Sea Water and Saline in Postoperative Endoscopic Sinus Surgery. *Journal of the Medical Association of Thailand.* 2008; 91(10): 1558-1563.
42. Hamdi IM. Effect of D-Panthenol on Corneal Epithelial Healing after Surface Laser Ablation. *Journal of Ophthalmology.* 2018; 6537413: 6. DOI: 10.1155/2018/6537413.
43. Hanck AB, Goffin H. Dexpanthenol (Ro 01-4709) in the treatment of constipation. *Acta Vitaminologica et Enzymologica.* 1982; 4(1-2): 87-97.